123 related articles for article (PubMed ID: 23388226)
1. Effects of two different treatments with continuous renal replacement therapy in patients with chronic renal dysfunction submitted to coronary invasive procedures.
Spini V; Cecchi E; Chiostri M; Landi D; Romano SM; Mattesini A; Gensini GF; Giglioli C
J Invasive Cardiol; 2013 Feb; 25(2):80-4. PubMed ID: 23388226
[TBL] [Abstract][Full Text] [Related]
2. Predictors of outcomes of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with chronic kidney disease.
Kim JH; Yang JH; Choi SH; Song YB; Hahn JY; Choi JH; Lee SH; Gwon HC
Am J Cardiol; 2014 Dec; 114(12):1830-5. PubMed ID: 25438909
[TBL] [Abstract][Full Text] [Related]
3. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Shehata M; Hamza M
Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
[TBL] [Abstract][Full Text] [Related]
4. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification according to the type of impaired renal function in patients with acute myocardial infarction treated with percutaneous coronary intervention.
Kowalczyk J; Lenarczyk R; Kowalski O; Swiatkowski A; Stabryła-Deska J; Kurek T; Honisz G; Kukulski T; Gasior M; Kalarus Z
Kardiol Pol; 2007 Jun; 65(6):635-43; discussion 644. PubMed ID: 17629825
[TBL] [Abstract][Full Text] [Related]
6. [The relationship between hyperuricemia and contrast-induced nephropathy in patients with chronic kidney disease undergoing percutaneous coronary intervention].
Liu YH; Tan N; Liu Y; Ye P; He YT; Ran P; Jiang L
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Sep; 41(9):740-3. PubMed ID: 24331800
[TBL] [Abstract][Full Text] [Related]
7. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention.
Abe M; Morimoto T; Akao M; Furukawa Y; Nakagawa Y; Shizuta S; Ehara N; Taniguchi R; Doi T; Nishiyama K; Ozasa N; Saito N; Hoshino K; Mitsuoka H; Toma M; Tamura T; Haruna Y; Kita T; Kimura T
Am J Cardiol; 2014 Aug; 114(3):362-8. PubMed ID: 24927973
[TBL] [Abstract][Full Text] [Related]
8. Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention.
Watabe H; Sato A; Hoshi T; Takeyasu N; Abe D; Akiyama D; Kakefuda Y; Nishina H; Noguchi Y; Aonuma K
Int J Cardiol; 2014 Jun; 174(1):57-63. PubMed ID: 24726211
[TBL] [Abstract][Full Text] [Related]
9. Serum creatinine ratio: a novel predictor of mortality after percutaneous coronary intervention in patients with normal and abnormal renal function.
Kini AS; Sarkar K; Rafael OC; Jakkula M; Kaplish D; Lee P; Suleman J; Krishnan P; Kim MC; Sharma SK
Catheter Cardiovasc Interv; 2009 Jul; 74(1):49-55. PubMed ID: 19288579
[TBL] [Abstract][Full Text] [Related]
10. An optimal strategy for coronary revascularization in patients with severe renal dysfunction.
Komiya T; Ueno G; Kadota K; Mitsudo K; Okabayashi H; Nishiwaki N; Hanyu M; Kimura T; Tanaka S; Marui A; Sakata R;
Eur J Cardiothorac Surg; 2015 Aug; 48(2):293-300. PubMed ID: 25416698
[TBL] [Abstract][Full Text] [Related]
11. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
[TBL] [Abstract][Full Text] [Related]
12. Impact of intravascular ultrasound-guided minimum-contrast coronary intervention on 1-year clinical outcomes in patients with stage 4 or 5 advanced chronic kidney disease.
Sakai K; Ikari Y; Nanasato M; Umetsu H; Okutsu M; Takikawa T; Sumitsuji S; Sadamatsu K; Takada M; Kato Y; Ogasawara N; Otowa K
Cardiovasc Interv Ther; 2019 Jul; 34(3):234-241. PubMed ID: 30343351
[TBL] [Abstract][Full Text] [Related]
13. Short and long term outcome of percutaneous coronary intervention with drug eluting stent and bare metal stent in patients with chronic kidney disease.
Resmini C; Di Cuia M; Ballocca F; D'Ascenzo F; Bollati M; Moretti C; Omedè PL; Sciuto F; Gaita F; Sheiban I
Minerva Cardioangiol; 2012 Dec; 60(6):573-80. PubMed ID: 23147435
[TBL] [Abstract][Full Text] [Related]
14. Volume-to-creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast-induced nephropathy.
Capodanno D; Ministeri M; Cumbo S; Dalessandro V; Tamburino C
Catheter Cardiovasc Interv; 2014 May; 83(6):907-12. PubMed ID: 23934631
[TBL] [Abstract][Full Text] [Related]
15. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention.
Parikh PB; Jeremias A; Naidu SS; Brener SJ; Lima F; Shlofmitz RA; Pappas T; Marzo KP; Gruberg L
Catheter Cardiovasc Interv; 2012 Sep; 80(3):352-7. PubMed ID: 22566286
[TBL] [Abstract][Full Text] [Related]
16. The prevention of contrast-induced nephropathy by simultaneous hemofiltration during coronary angiographic procedures: a comparison with periprocedural hemofiltration.
Choi MJ; Yoon JW; Han SJ; Choi HH; Song YR; Kim SG; Oh JE; Lee YK; Seo JW; Kim HJ; Noh JW; Koo JR
Int J Cardiol; 2014 Oct; 176(3):941-5. PubMed ID: 25200848
[TBL] [Abstract][Full Text] [Related]
17. Association of N-terminal pro-B-type natriuretic peptide with contrast-induced nephropathy and long-term outcomes in patients with chronic kidney disease and relative preserved left ventricular function.
Liu YH; Liu Y; Zhou YL; Yu DQ; He PC; Xie NJ; Li HL; Wei-Guo ; Chen JY; Tan N
Medicine (Baltimore); 2015 Apr; 94(13):e358. PubMed ID: 25837748
[TBL] [Abstract][Full Text] [Related]
18. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
[TBL] [Abstract][Full Text] [Related]
19. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention.
Mangiacapra F; Cavallari I; Barbato E; Ricottini E; Patti G; Vizzi V; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
Am J Cardiol; 2014 Apr; 113(7):1124-9. PubMed ID: 24507863
[TBL] [Abstract][Full Text] [Related]
20. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system.
Harjai KJ; Raizada A; Shenoy C; Sattur S; Orshaw P; Yaeger K; Boura J; Aboufares A; Sporn D; Stapleton D
Am J Cardiol; 2008 Mar; 101(6):812-9. PubMed ID: 18328846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
